Monday April 13, 2026
A funding-heavy start to the week, with strategic buyers and growth investors both signaling where momentum is building.
This week’s signal: neurovascular innovation and commercialization readiness are moving in parallel — with major acquisitions, fresh capital, and regulatory wins shaping who scales next.
8 things to watch this week:
1. 🧠 Stryker to Acquire Amplitude Vascular Systems
Stryker’s move into next-generation intravascular lithotripsy is a meaningful portfolio expansion in peripheral vascular, especially as calcified PAD remains a stubborn procedural challenge. For medtech leaders, this is another reminder that strategics are still willing to buy differentiated platforms that can slot cleanly into an existing commercial engine.
Endovascular Today
2. 💰 Gilead to acquire Tubulis in up to $5 billion deal to strengthen oncology pipeline
The size of the deal stands out, but so does the thesis: targeted delivery platforms still command premium strategic value when they bring credible clinical assets with them. Even for device operators, it is a useful signal that platform-plus-pipeline stories continue to attract real buyer urgency.
MedTech World
3. 🎯 86% of Medtech Teams Have Claims Their Evidence Can’t Back Up
In our Q1 client study, that’s what we found — claims outpacing evidence by enough to create real exposure in investor due diligence, health system reviews, or partner conversations. Most teams don’t see it because nothing breaks until the room actually matters.
We recently worked with a company preparing for a $25M Series A raise. Three weeks out, we found a claims-evidence gap that would have surfaced in due diligence. They fixed it before it cost them.
If you’re heading into a raise, a launch, or a strategic conversation in the next 90 days, this is the window to find out. We’re accepting a small number of medtech teams now.
4. 🔬 Monteris Medical Secures $28 Million in Growth Equity to Accelerate Revenue and Innovation in Minimally Invasive Neurosurgery
Monteris is raising growth capital to expand its U.S. commercial footprint, push technology development, and deepen clinical research around NeuroBlate. That combination matters: investors are still backing companies that can pair procedural differentiation with evidence generation and a clear path to broader adoption across health systems.
PR Newswire
5. 🤖 Luminai Raises $38 million Series B to Scale Intelligence Across Health System Operations
AI stories are everywhere, but Luminai’s angle is operational infrastructure rather than headline-grabbing automation theater. That makes this one worth watching: health systems are increasingly buying tools that promise workflow lift, measurable labor leverage, and cleaner execution in the back half of care delivery.
PR Newswire
6. 😴 ProSomnus gets FDA nod for latest sleep apnea therapy device
ProSomnus’ FDA clearance for RPMO₂ adds physiologic monitoring to oral appliance therapy, pushing sleep apnea treatment toward a more data-rich, feedback-driven model. Strategically, that is the interesting part: devices that do not just treat, but also generate monitoring data, tend to create stronger clinical and commercial positioning.
MassDevice
7. 🏥 Dimer Health Raises $13.5 Million | Thesis Care Announces $45 Million Series A
Both raises point at the same pressure point: health systems still need capacity, especially in moments where labor-intensive clinical work creates bottlenecks. Dimer’s post-discharge model and Thesis Care’s AI-supported clinical teams both reflect where buyers are spending now — on tools that promise operational relief without pretending clinicians are optional.
Healthcare IT Today
8. 🧬 Miracell Secures U.S. FDA Clearance for SMART M-CELL, Advancing Regenerative Therapies
Miracell’s 510(k) clearance adds another data point to the broader regenerative medicine buildout, especially around systems that aim to preserve cell viability while making extraction and concentration more usable in practice. It is still an earlier signal than some of the stories above, but it is a category worth tracking as procedural regenerative applications continue to mature.
BioPharma APAC
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.